CN117686476A - Mixed bimetal plasma array, preparation method, plasma array assisted laser desorption ionization mass spectrum detection method and application - Google Patents
Mixed bimetal plasma array, preparation method, plasma array assisted laser desorption ionization mass spectrum detection method and application Download PDFInfo
- Publication number
- CN117686476A CN117686476A CN202311708780.0A CN202311708780A CN117686476A CN 117686476 A CN117686476 A CN 117686476A CN 202311708780 A CN202311708780 A CN 202311708780A CN 117686476 A CN117686476 A CN 117686476A
- Authority
- CN
- China
- Prior art keywords
- noble metal
- plasma array
- sample
- metal nanoparticles
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000001698 laser desorption ionisation Methods 0.000 title claims abstract description 12
- 238000001819 mass spectrum Methods 0.000 title claims description 13
- 229910000510 noble metal Inorganic materials 0.000 claims abstract description 48
- 239000002082 metal nanoparticle Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 21
- 239000002777 nucleoside Substances 0.000 claims abstract description 14
- 239000002105 nanoparticle Substances 0.000 claims abstract description 13
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 41
- 239000011159 matrix material Substances 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000010970 precious metal Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002965 ELISA Methods 0.000 abstract description 5
- 238000004587 chromatography analysis Methods 0.000 abstract description 5
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 abstract description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 14
- 239000002207 metabolite Substances 0.000 description 12
- 229930010555 Inosine Natural products 0.000 description 10
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 10
- 229960003786 inosine Drugs 0.000 description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 7
- 229960005305 adenosine Drugs 0.000 description 7
- 238000003795 desorption Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 239000000956 alloy Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229910001020 Au alloy Inorganic materials 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229910001316 Ag alloy Inorganic materials 0.000 description 3
- 229910001260 Pt alloy Inorganic materials 0.000 description 3
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention relates to a quantitative detection technology, in particular to a mixed bimetal plasma array, a preparation method and a detection method and application of plasma array assisted laser desorption ionization mass spectrometry, wherein the plasma array is obtained by self-assembling positively charged noble metal nano particles and negatively charged noble metal nano particles, and the positively charged noble metal nano particles and the negatively charged noble metal nano particles are nano particles of different noble metals; or, at least the positively charged noble metal nanoparticles are double noble metal nanoparticles; or, at least the negatively charged noble metal nanoparticles are double noble metal nanoparticles. Compared with the prior art, the method solves the problems that in the prior art, the accurate quantitative detection of the nucleoside substances is difficult to carry out by a chromatography method and an enzyme-linked immunosorbent assay method, and detection inaccuracy is caused by strong background noise of MALDI MS in a low-quality area, realizes rapid and selective identification of specific molecules, and obtains the signal intensity of the specific molecules by a fingerprint.
Description
Technical Field
The invention relates to a quantitative detection technology, in particular to a mixed bimetal plasma array and a preparation method thereof, and a detection method and application of plasma array assisted laser desorption ionization mass spectrometry.
Background
The metabolites are located at the end of the biochemical pathway, providing a functional fingerprint of the physiological and pathophysiological state of the body. Disease-related processes, such as tumor progression, drug resistance, immune response and maintenance of pluripotency, are regulated by coordinated changes in metabolic enzymes and transporters and their corresponding metabolites. Therefore, the detection of the metabolic molecules has important significance in the aspects of disease diagnosis, treatment and the like.
Preferential, quantitative detection of conventional metabolites relies primarily on gas/liquid chromatography and mass spectrometry (GC/LC-MS). Both of these methods require cumbersome sample pretreatment and additional chromatographic run times (40 minutes) to process the clinical sample to address the composition complexity of the clinical sample and trace abundance of the target metabolite. It remains a significant challenge to establish an accurate and rapid quantitative analysis method to monitor metabolites in a clinically useful biological sample.
Matrix-assisted laser desorption/ionization MS (MALDI MS) is capable of rapid, sensitive and high throughput detection of metabolite molecules with the aid of a matrix, without or with only simple sample pretreatment for small amounts of sample (-nL). However, conventional organic matrices such as α -cyano-4-hydroxycinnamic acid (CHCA) and 2, 5-dihydroxybenzoic acid (DHB) present strong background noise in the low mass region (< m/z 700) due to self-dissociation, which hinders their use in metabolite detection.
In summary, currently quantitative detection of metabolites mainly relies on chromatography and enzyme-linked immunosorbent assay: 1) For the chromatography, the complex sample needs to be pretreated, and the problems of long detection time, high price and the like exist, so that the low-cost and high-flux detection of the actual complex sample is difficult to realize, and the method is difficult to be used for clinic. 2) For the ELISA, the detection time is long, the antibody is expensive, and the high-throughput and low-cost detection of the clinical complex sample is difficult to realize. In addition, the nucleoside substance has the problems of short half-life (for example, the half-life of adenosine is extremely short to a few seconds) and the like, and cannot be accurately and quantitatively detected by means of conventional chromatography and enzyme-linked immunosorbent assay. Therefore, there is a need to propose a method for preferential, quantitative detection of nucleoside substances.
Disclosure of Invention
The invention aims to solve at least one of the problems, and provides a mixed bimetal plasma array and a preparation method thereof, and a detection method and application of plasma array assisted laser desorption ionization mass spectrometry, so as to solve the problems that in the prior art, the chromatography and the enzyme-linked immunosorbent assay are difficult to accurately and quantitatively detect nucleoside substances, and the MALDI MS has strong background noise in a low-quality area to cause inaccurate detection, realize rapid and selective identification of specific molecules, and can acquire the signal intensity of the specific molecules through fingerprint, and the method has the advantages of simplicity in operation, high sensitivity, low cost and high detection flux, and has the potential of being applied to complex clinical samples.
The aim of the invention is achieved by the following technical scheme:
the first aspect of the invention discloses a mixed bimetallic plasma array, which is obtained by self-assembling positively charged noble metal nanoparticles and negatively charged noble metal nanoparticles, wherein,
the positively charged noble metal nanoparticles and the negatively charged noble metal nanoparticles are nanoparticles of different noble metals; or alternatively, the first and second heat exchangers may be,
at least the positively charged noble metal nanoparticles are double noble metal nanoparticles; or alternatively, the first and second heat exchangers may be,
at least the negatively charged noble metal nanoparticles are double noble metal nanoparticles.
Preferably, the noble metal nanoparticles include Ag nanoparticles, pt nanoparticles, au nanoparticles, and Pt/Au nanoparticles.
The second aspect of the invention discloses a method for preparing the mixed bimetal plasma array, which comprises the following steps:
s1: preparation of positively charged noble metal nanoparticles:
stirring a mixed metal source and a first end capping agent at room temperature, adding a reducing agent into the mixed solution, and standing away from light to obtain a suspension of positively charged noble metal nanoparticles;
s2: preparation of negatively charged noble metal nanoparticles:
heating and stirring the metal source to boil, adding a second end-capping agent into the boiled metal source and keeping the boiling state, and then continuously stirring in the natural cooling process to obtain a suspension of negatively charged noble metal nano particles;
s3: preparation of a plasma array:
dispersing the negatively charged noble metal nano particles prepared in the step S2 in oil, adding the positively charged aqueous suspension of the noble metal nano particles prepared in the step S1, vibrating, and self-assembling at a water-oil two-phase or oil-water-oil three-phase interface to form the mixed bimetal plasma array.
Preferably, the metal source comprises HAuCl 4 And H 2 PtCl 6 One or two of the following components; the first end capping agent comprises a cysteine solution; the second end capping agent comprises sodium citrate; the oil liquid comprises 1, 2-dichloroethane and n-hexane.
Preferably, in step S1, the stirring time is 20min, and the light-shielding standing time is 10min; in the step S2, the time for keeping the boiling state is 10min, and the time for continuing stirring in the natural cooling process is 15min; in step S3, the time of the oscillation is 30S.
Preferably, the volume ratio of the oil, negatively charged noble metal nanoparticles, and positively charged noble metal nanoparticles is 500:400:20.
the third aspect of the invention discloses a detection method of plasma array assisted laser desorption ionization mass spectrometry, which adopts the mixed bimetal plasma array as a matrix, or adopts the mixed bimetal plasma array prepared by any one of the methods as the matrix;
the detection method comprises the following steps:
s4: sample pretreatment:
adding the reaction sample into an extracting agent, vortex oscillating, centrifuging after freezing treatment, and taking supernatant;
s5: sample preparation:
preheating a target plate, transferring the plasma array to the target plate and drying, and dripping the sample processed in the step S4 on the plasma array and drying;
s6: sample detection:
in the matrix-assisted laser desorption ionization mass spectrometry, the sample prepared in the step S5 is subjected to mass spectrometry detection by adopting a positive ion reflection mode.
Preferably, the reaction sample comprises a blood sample, a biological sample, a food sample and an environmental sample; the extractant comprises the following components in percentage by volume: 2:1 methanol, acetonitrile and water.
Preferably, in step S4, the vortex shaking time is 30S, the freezing treatment is freezing for 2 hours at-20 ℃, and the centrifugation is centrifugation for 10 minutes at 12000rpm at 4 ℃; in the step S5, the preheating temperature is 0-100 ℃.
The fourth aspect of the invention discloses an application of the detection method of the plasma array assisted laser desorption ionization mass spectrum in quantitatively detecting nucleoside substances.
Noble metals are promising laser desorption/ionization mass spectrometry (ldims) matrix materials exhibiting superior surface plasmon effects and higher hot carrier effects, thereby improving desorption and ionization of analytes. According to the invention, the mixed double noble metal nano particles are self-assembled through a liquid-liquid interface or an oil-water-oil three-phase interface, so that a novel uniformly and densely arranged plasma array is prepared; the plasma array can preferentially detect specific metabolites (e.g., nucleosides) by enhancing the binding affinity between chemical groups (e.g., basic nitrogen heterocycles (base ring nitrogen), exocyclic ketone groups (exocyclic keto groups), imidazole groups, etc.) and noble metals.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a novel plasma array formed by self-assembly of mixed bimetal nano materials, which can be used as a matrix material of matrix-assisted laser desorption ionization mass spectrum and is used for quantitative detection of nucleoside substances.
The invention aims to utilize self-assembled plasma arrays to assist LDI MS to detect nucleoside substances preferentially and quantitatively. The mixed bimetal plasma array is combined with mass spectrum, and has extremely strong affinity to nucleoside substances.
The detection method can realize the rapid (several seconds) and accurate (R) of inosine and adenosine by only consuming 4 mu L of natural biological fluid 2 >0.99 Quantification).
Compared with the existing method, the method can rapidly and selectively identify the specific molecules and can acquire the signal intensity of the specific molecules through the fingerprint; the method has the advantages of simple operation, high sensitivity, low cost, high detection flux and potential of being applied to complex clinical samples.
Drawings
FIG. 1 is a schematic diagram of an experimental workflow for preferential metabolite detection in laser desorption/ionization mass spectrometry (LDI-MS) using a plasma array as a matrix;
FIG. 2 shows the results of detection of inosine and adenosine in clinical samples, wherein (a), (b) and (c) are respectively the standard curves of inosine detection by LDI MS, the results of detection of 23 samples by LDI-MS, and the consistency comparison of the results of detection of LDI-MS and ELSA kit; (d) (e) and (f) are respectively the standard curve of adenosine detected by LDI MS, 19 samples of LDI-MS detection results, and consistency comparison of LDI-MS and ELSA kit detection results;
FIG. 3 is a graph showing the characteristics of the plasma array (A2) obtained in example 1, the plasma array (A1) obtained in comparative example 1, and the plasma array (A3) obtained in comparative example 2,
(a) I: SEM image of A1, ii: SEM image of A2, iii: an SEM image of A3 was taken of the sample,
(b) I: when A1 is used as a matrix, inosine (1 mg mL) -1 ) Aspartic acid (1 mg mL) -1 ) Arginine (1 mg mL) -1 ) Mass spectrum intensity plot of ii):when A2 was used as a substrate, inosine (1 mg mL) -1 ) Aspartic acid (1 mg mL) -1 ) Arginine (1 mg mL) -1 ) Mass spectrum intensity profile of iii): when A3 is used as a matrix, inosine (1 mg mL) -1 ) Aspartic acid (1 mg mL) -1 ) Arginine (1 mg mL) -1 ) Is a mass spectrum intensity map of (2);
FIG. 4 shows the tendency of A2 as a matrix for detecting 37 small molecules by laser desorption/ionization mass spectrometry in application example 1;
fig. 5 is a mass spectrum of a plasma sample detected by A2-matrix assisted laser desorption/ionization mass spectrometry in application example 1.
Detailed Description
The invention will now be described in detail with reference to the drawings and specific examples.
In the examples below, the reagents used may be conventional commercial products, using methods well known in the art, unless specifically indicated.
Example 1
Step 1: preparation of instruments and reagents: matrix-assisted laser desorption ionization mass spectrometry adopts a positive ion reflection mode;
step 2: the preparation of the plasma array material comprises the following steps of;
step 2.1: pt/Au NPs (-) with negative surface charge were synthesized using sodium citrate as a capping agent.
In detail, HAuCl 4 And H 2 PtCl 6 The (1/2, v/v) mixed aqueous solution (50 mL,1 mM) was heated to boiling with vigorous stirring. Then, sodium citrate solution (5 ml,38.8 mm) was added rapidly to the mixture. After boiling for 10 minutes, the mixture solution is stirred for 15 minutes under the condition of no heating, and then Pt/Au NPs (-) can be obtained.
Step 2.2: by NaBH 4 As a reducing agent, cysteamine solution is used as a blocking agent to prepare Au NPs (+) with positive charges.
In detail, will 40mL 1.42mM HAuCl 4 Mix with 400. Mu.L 213mM cysteamine solution and stir at room temperature for 20 minutes. Subsequently, 10. Mu.L of 10mM NaBH was added 4 Adding the solution into the mixture, and standing the solution in dark placeAnd obtaining Au NPs (+)' after 10 min.
Step 2.3: the plasma array is prepared by adopting an improved water-oil interface self-assembly method, and through simple electrostatic interaction, self-assembling noble metal nano particles with opposite charges on a liquid-liquid interface.
First, 400. Mu.L of negatively charged metal NPs (Pt/Au NPs (-)) were dispersed in 500. Mu.L of 1, 2-dichloroethane. Then, 20. Mu.L of positively charged metal NP (Au NPs (+) aqueous suspension) was added thereto. The mixture was vigorously shaken for 30 seconds to form a bright nanofilm (i.e., a plasma array) at the two-phase interface.
Step 2.4: the above-mentioned plasma array, denoted as A2, was used as a substrate;
step 3: sample pretreatment: adding 150 μl of extracting agent (methanol: acetonitrile: water=2:2:1 (v: v)) into 50 μl of plasma, vortex shaking for 30s, placing in a refrigerator at-20deg.C for 2 hr, centrifuging (12000 rpm,10min, 4deg.C), and collecting supernatant;
step 4: sample preparation is performed on a target plate, comprising the steps of:
step 4.1: heating the target plate and controlling the temperature to 30 ℃;
step 4.2: taking the plasma subarray prepared in the step 2 as a matrix, transferring the matrix onto a target plate, and drying for later use;
step 4.3: taking the sample pretreated in the step 3, dripping the sample on a plasma array, and drying the sample for later use;
step 5: mass spectrum detection is carried out on the sample points dripped on the target plate;
step 6: and analyzing the mass spectrum detection result to obtain a conclusion.
Comparative example 1
This comparative example is substantially identical to the protocol of example 1, except that an Au plasma array, designated A1, was prepared and synthesized from Au NPs (+) and Au NP (-).
Comparative example 2
This comparative example is essentially identical to the protocol of example 1, except that a Pt plasma array, designated A3, was prepared, synthesized from Pt NPs (+) and Pt NPs (-).
Characterization results:
from the scanning electron microscope results (fig. 3 (a)), the A2 array was more uniformly and tightly arranged than the A1 and A3 arrays, and showed the highest intensity among the 3 indicator molecules of inosine, aspartic acid, and arginine (fig. 3 (b)).
Fig. 1 shows a schematic diagram of an experimental workflow of preferential metabolite detection using a plasma array as a matrix in laser desorption/ionization mass spectrometry (ldims), wherein fig. 1 (a) is a schematic diagram of a preparation process of self-assembly of the matrix (plasma array) through a liquid-liquid interface, fig. 1 (b) shows a schematic diagram of preferential detection of specific metabolites (such as nucleosides) by the plasma array, and fig. 1 (c) shows a schematic diagram of accurate quantification of nucleoside substances in a trace serum sample by the plasma array assisted ldims.
In fig. 2, the detection results of ldims (using plasma array A2 as a substrate) are taken as examples of inosine and adenosine, and it can be seen that the detection results of the method are basically consistent with the detection results of a commercial kit (ELISA kit), and the comparison of the detection results of the two results shows that the consistency is more than 98%, which indicates that the method has excellent accuracy.
Application example 1: affinity detection of 37 Small molecules
Step 1: preparation of instruments and reagents: matrix-assisted laser desorption ionization mass spectrometry, which adopts a cation reflection mode for detection;
step 2: preparation of plasma array materials: in accordance with the protocol in example 1, A2;
step 3: configuration of 37 small molecule solutions: at 1mg mL -1 Sodium chloride solution of (2) is used as solvent, and 1mM solution is prepared respectively;
among them, 37 kinds of small molecules are mainly classified into 6 major categories: including nucleosides (inosine, guanosine, adenosine, cytidine, thymidine), pyrimidines (cytosine, thymine), amino acids (aspartic acid, glutamic acid, histidine, arginine, lysine, asparagine, glutamine, serine, alanine, glycine, cysteine, methionine, tyrosine, isoleucine, phenylalanine, proline, valine, leucine), sugars (raffinose, glucose, cellobiose), hormones (estradiol, androstenedione, testosterone, estrone), other classes (vitamin B1, nicotinamide, lactic acid, ascorbic acid, cholesterol);
step 4: the mass spectrum signal intensity of 37 small molecules (1 mM) was detected under a mass spectrometer using A2 as a matrix, and data analysis was performed, and the results are shown in FIG. 4. Shows a stronger tendency to nucleoside.
Application example 2: detection of authentic plasma samples
Step 1: preparation of instruments and reagents: matrix-assisted laser desorption ionization mass spectrometry, which adopts a cation reflection mode for detection;
step 2: preparation of plasma array materials: in accordance with the protocol in example 1, A2;
step 3: pretreatment of clinical samples: taking 50. Mu.L of plasma sample, adding 150. Mu.L of extractant (methanol: acetonitrile: water=2:2:1, v/v/v), swirling for 30s, standing in a refrigerator at-20deg.C for 2h, centrifuging (12000 rpm,15min, 4deg.C), and collecting supernatant for use;
step 4: taking A2 as a matrix, transferring to a target plate, drying, dripping 2 mu L of the sample in the step 3, drying at room temperature, detecting a clinical plasma sample under a mass spectrometer, and observing fragment peaks of guanosine, adenosine and inosine when m/z is 174.01, 180.11 and 181.01 respectively when the mass spectrometer is shown in a result of a mass spectrometer shown in FIG. 5.
In other embodiments, the matrix material is not limited to Pt/Au alloy materials, but extends to matrix materials that are commonly used with laser desorption ionization mass spectrometry, such as Au/Ag alloy materials, pt/Ag alloy materials, and the like. And the matrix material can be prepared from a combination of different noble metal nanoparticles, such as: the Pt/Au alloy material can also be prepared from Au NPs (+) and Pt NPs (-), pt/Au NPs (+) and Au NPs (-), and the like; the Au/Ag alloy material can be prepared from Au NPs (+) and Ag NPs (-), au/Ag NPs (+) and Ag NPs (-), and the like; the main difference from example 1 is that the ratio of the configuration is different, and the optimal ratio or the preferable ratio range is selected according to experimental optimization.
In other embodiments, the reaction system sample may be extended to other biological samples (e.g., urine, sweat, saliva, pericardial fluid, etc.), food samples (e.g., milk), environmental samples (waste, river water), etc.
The previous description of the embodiments is provided to facilitate a person of ordinary skill in the art in order to make and use the present invention. It will be apparent to those skilled in the art that various modifications can be readily made to these embodiments and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments, and those skilled in the art, based on the present disclosure, should make improvements and modifications without departing from the scope of the present invention.
Claims (10)
1. A mixed bimetal plasma array is characterized by being obtained by self-assembling positively charged noble metal nano particles and negatively charged noble metal nano particles,
the positively charged noble metal nanoparticles and the negatively charged noble metal nanoparticles are nanoparticles of different noble metals; or alternatively, the first and second heat exchangers may be,
at least the positively charged noble metal nanoparticles are double noble metal nanoparticles; or alternatively, the first and second heat exchangers may be,
at least the negatively charged noble metal nanoparticles are double noble metal nanoparticles.
2. The hybrid bimetallic plasmonic array of claim 1, wherein the noble metal nanoparticles include Ag nanoparticles, pt nanoparticles, au/Ag nanoparticles, and Pt/Au nanoparticles.
3. A method of making a hybrid bimetallic plasma array as claimed in claim 1 or 2, comprising the steps of:
s1: preparation of positively charged noble metal nanoparticles:
stirring a mixed metal source and a first end capping agent at room temperature, adding a reducing agent into the mixed solution, and standing away from light to obtain a suspension of positively charged noble metal nanoparticles;
s2: preparation of negatively charged noble metal nanoparticles:
heating and stirring the metal source to boil, adding a second end-capping agent into the boiled metal source and keeping the boiling state, and then continuously stirring in the natural cooling process to obtain a suspension of negatively charged noble metal nano particles;
s3: preparation of a plasma array:
dispersing the suspension of the noble metal nano particles with negative charges prepared in the step S2 in oil, adding the suspension of the noble metal nano particles with positive charges prepared in the step S1, vibrating, and self-assembling at a water-oil two-phase interface or an oil-water-oil three-phase interface to form the mixed bimetal plasma array.
4. The method of claim 3, wherein the metal source comprises HAuCl 4 And H 2 PtCl 6 One or two of the following components; the first end capping agent comprises a cysteine solution; the second end capping agent comprises sodium citrate; the oil liquid comprises 1, 2-dichloroethane and n-hexane.
5. The method for preparing a mixed bimetal plasma array according to claim 3, wherein in the step S1, the stirring time is 20min, and the light-shielding standing time is 10min; in the step S2, the time for keeping the boiling state is 10min, and the time for continuing stirring in the natural cooling process is 15min; in step S3, the time of the oscillation is 30S.
6. A method of preparing a hybrid bimetallic plasma array as claimed in claim 3, wherein the volume ratio of oil, negatively charged precious metal nanoparticles to positively charged precious metal nanoparticles is 500:400:20.
7. a method for detecting plasma array assisted laser desorption ionization mass spectrometry, which is characterized in that the mixed bimetal plasma array according to claim 1 or 2 is adopted as a matrix, or the mixed bimetal plasma array prepared by the method according to any one of claims 3 to 6 is adopted as a matrix;
the detection method comprises the following steps:
s4: sample pretreatment:
adding the reaction sample into an extracting agent, vortex oscillating, centrifuging after freezing treatment, and taking supernatant;
s5: sample preparation:
preheating a target plate, transferring the plasma array to the target plate and drying, and dripping the sample processed in the step S4 on the plasma array and drying;
s6: sample detection:
in the matrix-assisted laser desorption ionization mass spectrometry, the sample prepared in the step S5 is subjected to mass spectrometry detection by adopting a positive ion reflection mode.
8. The method for detecting plasma-array assisted laser desorption ionization mass spectrometry of claim 7 wherein the reaction sample comprises a blood sample, a biological sample, a food sample and an environmental sample; the extractant comprises the following components in percentage by volume: 2:1 methanol, acetonitrile and water.
9. The method for detecting plasma array assisted laser desorption ionization mass spectrometry according to claim 7, wherein in the step S4, the vortex oscillation time is 30S, the freezing treatment is freezing for 2h at-20 ℃, and the centrifugation is centrifugation for 10min at 12000rpm at 4 ℃; in the step S5, the preheating temperature is 0-100 ℃.
10. Use of a detection method of a plasma array assisted laser desorption ionization mass spectrum according to any one of claims 7 to 9 for quantitative detection of nucleoside substances.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311708780.0A CN117686476A (en) | 2023-12-13 | 2023-12-13 | Mixed bimetal plasma array, preparation method, plasma array assisted laser desorption ionization mass spectrum detection method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311708780.0A CN117686476A (en) | 2023-12-13 | 2023-12-13 | Mixed bimetal plasma array, preparation method, plasma array assisted laser desorption ionization mass spectrum detection method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117686476A true CN117686476A (en) | 2024-03-12 |
Family
ID=90129761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311708780.0A Pending CN117686476A (en) | 2023-12-13 | 2023-12-13 | Mixed bimetal plasma array, preparation method, plasma array assisted laser desorption ionization mass spectrum detection method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117686476A (en) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101042377A (en) * | 2006-03-20 | 2007-09-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Method and reagent kit for enriching and sequencing peptide fragment containing histidine |
CN101175546A (en) * | 2005-04-05 | 2008-05-07 | 蛋白质发现公司 | Improved methods and devices for concentration and fractionation of analytes for chemical analysis including matrix-assisted laser desorption/ionization (maldi) mass spectrometry (ms) |
US20110165586A1 (en) * | 2009-10-12 | 2011-07-07 | Korea Advanced Institute Of Science And Technology | Detection Method of Bio-Chemical Material Using Surface-Enhanced Raman Scattering |
US20120104243A1 (en) * | 2010-11-03 | 2012-05-03 | University Of North Texas | Silver and Silver Nanoparticle MALDI Matrix Utilizing Online Soft Landing Ion Mobillity |
CN103357403A (en) * | 2013-07-08 | 2013-10-23 | 华南理工大学 | Method for preparing carbon-supported fuel cell double-metal electro-catalyst through electrostatic self-assembly |
CN104614360A (en) * | 2015-01-16 | 2015-05-13 | 中国科学院合肥物质科学研究院 | Method for assembling precious metal nanocrystalline on surface of conical fiber |
CN105929017A (en) * | 2016-06-14 | 2016-09-07 | 南京大学 | Application of molybdenum disulfide/nanosilver composite serving as matrix to matrix-assisted laser desorption/ionization time of flight mass spectrometry |
CN106807941A (en) * | 2015-11-30 | 2017-06-09 | 上海交通大学 | A kind of noble metal core-shell structure nanometer particle and its preparation and application |
CN107643337A (en) * | 2017-09-18 | 2018-01-30 | 亿纳谱(浙江)生物科技有限公司 | A kind of matrix and preparation method thereof, biology sample detection method |
CN109632938A (en) * | 2019-01-11 | 2019-04-16 | 中国科学院化学研究所 | Application of the silver nano-grain of poly-dopamine modification in mass spectral analysis detection |
CN109665489A (en) * | 2018-12-20 | 2019-04-23 | 苏州大学 | A method of in the two-way controllable self assembly difference charged metal nanoparticle of substrate surface |
US20190308155A1 (en) * | 2016-11-30 | 2019-10-10 | Sebastian Kunz | Improved precious metal nanoparticles |
CN111426741A (en) * | 2020-04-21 | 2020-07-17 | 四川大学 | Method for performing liquid biopsy based on nano material assisted MA L DI-TOF MS |
CN111747447A (en) * | 2020-07-07 | 2020-10-09 | 浙江亿纳谱生命科技有限公司 | Core-shell metal matrix and preparation and application thereof |
CN112730323A (en) * | 2020-12-18 | 2021-04-30 | 上海交通大学 | Novel hybrid metal nano material, preparation method thereof and application thereof in matrix-assisted laser desorption ionization mass spectrometry |
CN116148340A (en) * | 2022-11-09 | 2023-05-23 | 汕头大学 | Gold nano-particle array with strong stability and reusability and preparation and application thereof |
CN116908279A (en) * | 2023-07-20 | 2023-10-20 | 上海市胸科医院 | Method for monitoring metabolite reaction based on matrix-assisted laser desorption ionization mass spectrometry |
-
2023
- 2023-12-13 CN CN202311708780.0A patent/CN117686476A/en active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101175546A (en) * | 2005-04-05 | 2008-05-07 | 蛋白质发现公司 | Improved methods and devices for concentration and fractionation of analytes for chemical analysis including matrix-assisted laser desorption/ionization (maldi) mass spectrometry (ms) |
CN101042377A (en) * | 2006-03-20 | 2007-09-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Method and reagent kit for enriching and sequencing peptide fragment containing histidine |
US20110165586A1 (en) * | 2009-10-12 | 2011-07-07 | Korea Advanced Institute Of Science And Technology | Detection Method of Bio-Chemical Material Using Surface-Enhanced Raman Scattering |
US20120104243A1 (en) * | 2010-11-03 | 2012-05-03 | University Of North Texas | Silver and Silver Nanoparticle MALDI Matrix Utilizing Online Soft Landing Ion Mobillity |
CN103357403A (en) * | 2013-07-08 | 2013-10-23 | 华南理工大学 | Method for preparing carbon-supported fuel cell double-metal electro-catalyst through electrostatic self-assembly |
CN104614360A (en) * | 2015-01-16 | 2015-05-13 | 中国科学院合肥物质科学研究院 | Method for assembling precious metal nanocrystalline on surface of conical fiber |
CN106807941A (en) * | 2015-11-30 | 2017-06-09 | 上海交通大学 | A kind of noble metal core-shell structure nanometer particle and its preparation and application |
CN105929017A (en) * | 2016-06-14 | 2016-09-07 | 南京大学 | Application of molybdenum disulfide/nanosilver composite serving as matrix to matrix-assisted laser desorption/ionization time of flight mass spectrometry |
US20190308155A1 (en) * | 2016-11-30 | 2019-10-10 | Sebastian Kunz | Improved precious metal nanoparticles |
CN107643337A (en) * | 2017-09-18 | 2018-01-30 | 亿纳谱(浙江)生物科技有限公司 | A kind of matrix and preparation method thereof, biology sample detection method |
CN109665489A (en) * | 2018-12-20 | 2019-04-23 | 苏州大学 | A method of in the two-way controllable self assembly difference charged metal nanoparticle of substrate surface |
CN109632938A (en) * | 2019-01-11 | 2019-04-16 | 中国科学院化学研究所 | Application of the silver nano-grain of poly-dopamine modification in mass spectral analysis detection |
CN111426741A (en) * | 2020-04-21 | 2020-07-17 | 四川大学 | Method for performing liquid biopsy based on nano material assisted MA L DI-TOF MS |
CN111747447A (en) * | 2020-07-07 | 2020-10-09 | 浙江亿纳谱生命科技有限公司 | Core-shell metal matrix and preparation and application thereof |
CN112730323A (en) * | 2020-12-18 | 2021-04-30 | 上海交通大学 | Novel hybrid metal nano material, preparation method thereof and application thereof in matrix-assisted laser desorption ionization mass spectrometry |
CN116148340A (en) * | 2022-11-09 | 2023-05-23 | 汕头大学 | Gold nano-particle array with strong stability and reusability and preparation and application thereof |
CN116908279A (en) * | 2023-07-20 | 2023-10-20 | 上海市胸科医院 | Method for monitoring metabolite reaction based on matrix-assisted laser desorption ionization mass spectrometry |
Non-Patent Citations (3)
Title |
---|
HUA ZHANG等: "In situ dynamic tracking of heterogeneous nanocatalytic processes by shell-isolated nanoparticle-enhanced Raman spectroscopy", NATURE COMMUNICATIONS, vol. 8, 24 May 2017 (2017-05-24), pages 3 - 4, XP055648353, DOI: 10.1038/ncomms15447 * |
王方丽等: "基于纳米材料的表面辅助激光解吸离子化质谱研究", 化学进展, vol. 27, no. 05, 31 May 2015 (2015-05-31) * |
赵亚然等: "双功能金属纳米粒子在表/界面催化反应SERS研究中的应用", 中国科学:化学, vol. 49, no. 05, 31 May 2019 (2019-05-31) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lageveen-Kammeijer et al. | Highly sensitive CE-ESI-MS analysis of N-glycans from complex biological samples | |
Sekuła et al. | Silver nanostructures in laser desorption/ionization mass spectrometry and mass spectrometry imaging | |
JP7199392B2 (en) | Method for detecting estradiol by mass spectrometry | |
Zhu et al. | Highly sensitive detection of clenbuterol using competitive surface-enhanced Raman scattering immunoassay | |
Baranov et al. | A sensitive and quantitative element-tagged immunoassay with ICPMS detection | |
Wu et al. | Gold nanoparticles as assisted matrices for the detection of biomolecules in a high-salt solution through laser desorption/ionization mass spectrometry | |
Sun et al. | Designed microdevices for in vitro diagnostics | |
JP6151291B2 (en) | Detection method of dihydrotestosterone by mass spectrometry | |
Blackburn | Advances in the quantitation of therapeutic insulin analogues by LC–MS/MS | |
Wu et al. | A plasmonic mass spectrometry approach for detection of small nutrients and toxins | |
Agoston et al. | Rapid isolation and detection of erythropoietin in blood plasma by magnetic core gold nanoparticles and portable Raman spectroscopy | |
AU1420692A (en) | Methods and apparatus for improved luminescence assays | |
FR2810739A1 (en) | Electrochemical detection or quantification of biological substance coupled to metallic colloidal particle, first dissolves particle by chemical treatment | |
WO2010075449A1 (en) | Mass spectrometry assay for congenital adrenal hyperplasia | |
Marty et al. | Ultra-thin layer MALDI mass spectrometry of membrane proteins in nanodiscs | |
Turney et al. | Functionalized nanoparticles for liquid atmospheric pressure matrix‐assisted laser desorption/ionization peptide analysis | |
Liu et al. | Protein quantitation using Ru-NHS ester tagging and isotope dilution high-pressure liquid chromatography–inductively coupled plasma mass spectrometry determination | |
Gjergjizi et al. | SERS-based ultrafast and sensitive detection of luteinizing hormone in human serum using a passive microchip | |
Ma et al. | Mass spectrometry methods for in situ analysis of clinical biomolecules | |
Muthu et al. | The ongoing evolution of laser desorption/ionization mass spectrometry: Some observations on current trends and future directions | |
Li et al. | Instrument-free enrichment and detection of phosphopeptides using paper-based Phos-PAD | |
Bai et al. | Synthesis of zwitterionic polymer modified graphene oxide for hydrophilic enrichment of N-glycopeptides from urine of healthy subjects and patients with lung adenocarcinoma | |
Bhat et al. | Synthesis, characterization and application of modified Pd nanoparticles as preconcentration probes for selective enrichment/analysis of proteins via hydrophobic interactions from real‐world samples using nanoparticle‐liquid‐liquid microextraction coupled to matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry | |
Xu et al. | Highly sensitive and multiplexed mass spectrometric immunoassay techniques and clinical applications | |
Qin et al. | In situ microliter-droplet anodic stripping voltammetry of copper stained on the gold label after galvanic replacement reaction enlargement for ultrasensitive immunoassay of proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |